文献速递结核与非结核分枝杆菌

临床评估中的候选抗结核药物与治疗方案

Candidate anti-tuberculosis medicines and regimens under clinical evaluation.
PubMed 文献 · Clin Microbiol Infect · 2024-06-22

结核病仍是全球感染性疾病死亡首因,现有治疗疗程长且不良反应多,耐药问题突出。本文综述了临床评估中的新型抗结核药物(包括蛋白质合成抑制剂、呼吸链抑制剂、细胞壁抑制剂和胆固醇代谢抑制剂)以及评估治疗方案的临床试验平台创新。大量候选药物和试验设计创新为改善结核治疗带来希望。

要点

  • 多种新型抗结核药物正处于临床评估阶段,涵盖蛋白质合成、呼吸链、细胞壁和胆固醇代谢等靶点。
  • 临床试验设计正从评估单一药物转向评估完整治疗方案。
  • 候选药物和试验设计创新为改善药物敏感及耐药结核治疗带来希望。

核心结论

  • 大量潜在抗结核候选药物及评估治疗方案而非单一药物的临床试验设计创新,为改善结核治疗带来希望。

研究设计与样本

  • 综述,检索范围包括新型抗结核药物的临床前和临床研究。

主要发现

  • 临床评估中的新型抗结核药物包括蛋白质合成抑制剂(噁唑烷酮类和氧硼杂环类)、呼吸链抑制剂(二芳基喹啉类和细胞色素bc1复合物抑制剂)、细胞壁抑制剂(癸异戊烯基磷酰-β-d-核糖2'-差向异构酶抑制剂、硫代酰胺类和碳青霉烯类)以及胆固醇代谢抑制剂。
  • 临床试验平台正转向评估治疗方案而非单一药物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis (TB) is the leading cause of mortality by an infectious disease worldwide. Despite national and international efforts, the world is not on track to end TB by 2030. Antibiotic treatment of TB is longer than for most infectious diseases and is complicated by frequent adverse events. To counter emerging Mycobacterium tuberculosis drug resistance and provide effective, safe drug treatments of shorter duration, novel anti-TB medicines, and treatment regimens are needed. Through a joint global effort, more candidate medicines are in the clinical phases of drug development than ever before. OBJECTIVES: To review anti-TB medicines and treatment regimens under clinical evaluation for the future treatment of drug-susceptible and drug-resistant TB. SOURCES: Pre-clinical and clinical studies on novel anti-TB drugs. CONTENT: Description of novel protein synthesis inhibitors (oxazolidinones and oxaboroles), respiratory chain inhibitors (diarylquinolines and cytochrome bc1 complex inhibitor), cell wall inhibitors (decaprenylphosphoryl-β-d-ribose 2'-epimerase, inhibitors, thioamides, and carbapenems), and cholesterol metabolism inhibitor currently evaluated in clinical trials and novel clinical trial platforms for the evaluation of treatment regimens, rather than single entities. IMPLICATIONS: A large number of potential anti-TB candidate medicines and innovations in clinical trial design for the evaluation of regimens, rather than single medicines, provide hope for improvements in the treatment of TB.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Hoelscher M, Barros-Aguirre D, Dara M, et al. Candidate anti-tuberculosis medicines and regimens under clinical evaluation. Clin Microbiol Infect. 2024. PMID: 38909687. doi:10.1016/j.cmi.2024.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。